Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organsSensitivity in those with previously diagnosed cardiac disease was 100%...

Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition elementThis novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for...

Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleenAT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrilsAT-02 binds potently to multiple types of amyloid...

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...